Robins Kaplan

Robins Kaplan's life sciences group is made of almost 30 attorneys, a number of whom contribute to the firm's notable ranking in Hatch-Waxman disputes for generic drug makers. According to a client, the firm is "thoughtful and methodical in its work on our behalf in a number of high-stakes litigation matters," and "repeatedly demonstrates that our interests are 'top of mind' for them."

Jake Holdreith serves as life sciences industry lead at the firm, and is focused on representing generic drug companies in patent litigation. He recently secured a dismissal for Collegium in an action brought by Purdue Pharma alleging the client's updated clinical information infringed its patents. "Jake is not just a lawyer, he is an advisor," a client says. "He has a knack for understanding not only the legal ramifications of litigation strategy, but also how they interplay with business strategy."

Ronald Schutz is another one of the firm's distinguished IP trial lawyers, and serves as managing partner of the New York office. He has been active for client Puget Bioventures in multiple patent suits, including one case that resulted in a stay being lifted after Puget's patent claims were upheld by the Patent Office.